Compare TTC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | HALO |
|---|---|---|
| Founded | 1914 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.8B |
| IPO Year | 1994 | 2001 |
| Metric | TTC | HALO |
|---|---|---|
| Price | $99.05 | $70.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $91.00 | $78.18 |
| AVG Volume (30 Days) | 750.5K | ★ 2.0M |
| Earning Date | 03-19-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.17 | 2.56 |
| Revenue | ★ $2,618,650,000.00 | $151,862,000.00 |
| Revenue This Year | $4.34 | $28.38 |
| Revenue Next Year | $4.57 | $12.72 |
| P/E Ratio | $31.28 | ★ $27.12 |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $62.34 | $47.50 |
| 52 Week High | $102.32 | $82.22 |
| Indicator | TTC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 43.13 |
| Support Level | $72.39 | $67.94 |
| Resistance Level | $102.32 | $74.92 |
| Average True Range (ATR) | 2.32 | 2.52 |
| MACD | -0.71 | -0.76 |
| Stochastic Oscillator | 37.02 | 17.94 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.